Circulating cancer cells

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Mavroudis, D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Circulating tumour cells; Micrometastasis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER CELL; CANCER RELAPSE; CANCER STAGING; CELL ASSAY; CELL POPULATION; CELL STRUCTURE; CIRCULATING CANCER CELL; COLORECTAL CANCER; CONFERENCE PAPER; DENSITY GRADIENT CENTRIFUGATION; DISEASE COURSE; DISEASE FREE SURVIVAL; ENRICHMENT CULTURE; ESOPHAGUS CARCINOMA; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; INDIVIDUALIZATION; LASER SCANNING CYTOMETRY; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MICROFLUIDIC ANALYSIS; NUCLEIC ACID ANALYSIS; OVERALL SURVIVAL; PATIENT CARE; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STANDARDIZATION; TREATMENT OUTCOME; TUMOR BIOPSY;

CELL SEPARATION; EARLY DETECTION OF CANCER; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 78649390529     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq378     Document Type: Conference Paper

References (52)

1. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
2. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91: 1113-1124.
3. Schoenfeld A, Kruger KH, Gomm J et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997; 33: 854-861.
4. Stathopoulou A, Mavroudis D, Perraki M et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res 2003; 23: 1883-1890.
5. Berois N, Varangot M, Aizen B et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1and CEA using RT-PCR. Eur J Cancer 2000; 36: 717-723.
6. Bossolasco P, Ricci C, Farina G et al. Detection of micrometastatic cells in breast cancer by RT-PCR for the mammaglobin gene. Cancer Detect Prev 2002; 26: 60-63.
7. Pinzani P, Salvadori B, Simi L et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 2006; 37: 711-718.
8. Wong NS, Kahn HJ, Zhang L et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 2006; 99: 63-69.
9. Ring AE, Zabaglo L, Ormerod MG et al. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005; 92: 906-912.
10. Smith BM, Slade MJ, English J et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000; 18: 1432-1439.
11. Riethdorf S, Fritsche H, Muller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-928.
12. Fehm T, Hoffmann O, Aktas B et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11: R59.
13. Pachmann K, Clement JH, Schneider CP et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005; 43: 617-627.
14. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1239.
15. Alix-Panabieres C, Vendrell JP, Pelle O et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007; 53: 537-539.
16. Stathopoulou A, Gizi A, Perraki M et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res 2003; 9: 5145-5151.
17. Zippelius A, Kufer P, Honold G et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997; 15: 2701-2708.
18. Kowalewska M, Chechlinska M, Markowicz S et al. The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer 2006; 42: 2671-2674.
19. Stathopoulou A, Ntoulia M, Perraki M et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer 2006; 119: 1654-1659.
20. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006; 13: 1033-1067.
21. Van der Auwera I, Peeters D, Bennoy IH et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010; 102: 276-284.
22. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
23. Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20: 3404-3412.
24. Xenidis N, Perraki M, Kafousi M et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24: 3756-3762.
25. Ignatiadis M, Xenidis N, Perraki M et al. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early breast cancer. J Clin Oncol 2007; 25: 5194-5202.
26. Xenidis N, Ignatiadis M, Apostolaki S et al. Cytokeratin-19 mRNA-Positive Circulating Tumor Cells after Adjuvant Chemotherapy in Patients with Early Breast Cancer. J Clin Oncol 2009; 27: 2177-2184.
27. Xenidis N, Markos V, Apostolaki S et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007; 18: 1623-1631.
28. Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the German SUCCESS-Trial
29. Pachmann K, Camara O, Kavallaris A et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26: 1208-1215.
30. Cohen SJ, Punt CJ, Iannotti N et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221.
31. Wong SC, Chan CM, Ma BB et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 2009; 5: 1005-1012.
32. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
33. Chen TF, Jiang GL, Fu XL et al. CK19 mRNA expression measured by reversetranscription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 2007; 56: 105-114.
34. Yie SM, Lou B, Ye SR et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 2009; 63: 284-290.
35. Cao M, Yie SM, Wu SM et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 2009; 26: 751-758.
36. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging- predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409.
37. Cohen SJ, Punt CJ, Iannotti N et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-1229.
38. Rahbari NN, Aigner M, Thorlund K et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010; 138: 1714-1726.
39. Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 9393-9398.
40. Kallergi G, Mavroudis D, Georgoulias V et al. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 2007; 13: 79-88.
41. Fehm T, Sagalowsky A, Clifford E et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002; 8: 2073-2084.
42. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
43. Smirnov DA, Zweitzig DR, Foulk BW et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005; 65: 4993-4997.
44. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
45. Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007; 9: R74.
46. Bozionellou V, Mavroudis D, Perraki M et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNApositive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004; 10: 8185-8194.
47. Klein CA, Blankenstein TJ, Schmidt-Kittler O et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683-689.
48. Meng S, Tripathy D, Frenkel EP et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-8162.
49. Kallergi G, Agelaki S, Kalykaki A et al. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 2008; 10: R80.
50. Kallergi G, Markomanolaki H, Giannoukaraki V et al. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 2009; 11: R84.
51. Wulfing P, Borchard J, Buerger H et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006; 12: 1715-1720.
52. Theodoropoulos PA, Polioudaki H, Agelaki S et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288: 99-106.